Search / Trial NCT06235047

Liposomal Doxorubicin-containing Front-line Treatment in Elderly Patients With HL (HL-MVD)

Launched by FEDERICO II UNIVERSITY · Jan 23, 2024

Trial Information

Current as of December 21, 2024

Completed

Keywords

C Hl >60y Liposomal Doxorubicin

ClinConnect Summary

Classic Hodgkin lymphoma (c-HL) is a neoplasm that originates from B lymphocytes and represents 10% of all lymphomas. The most affected age group is between 20 and 30 years of age, with a second peak in the epidemiological distribution involving patients over 60 years of age.

Elderly patients often present with already advanced disease stages and B symptoms. On the other hand, these patients often have multiple comorbidities and reduced fitness and this can limit the therapeutic possibilities with curative intent in terms of doses and adherence to the timing foreseen by the therapeutic pro...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • previously untreated, biopsy-proven c-HL
  • Ann Arbor stage III or IV
  • ECOG PS 0-3
  • LVEF≥50% at echocardiographic assessment
  • human immunodeficiency virus negativity.
  • any GLS value
  • Exclusion Criteria:
  • Ann Arbor stage I or II,
  • concomitant major illnesses
  • creatinine clearance \<30 ml/min
  • serum transaminases more than three times the normal value
  • total bilirubin \>3.4 mg/dl
  • absolute neutrophil count \<500/mm 3
  • hemoglobin level \<9 g/dL
  • platelet count \<75 000/mm 3
  • Myocardial infarction represented an exclusion only if diagnosed within 3 months prior to MVD start.

About Federico Ii University

Federico II University, located in Naples, Italy, is a prestigious academic institution with a strong emphasis on advanced research and clinical innovation. As a clinical trial sponsor, the university is committed to fostering the development of novel therapeutic interventions and enhancing patient care through rigorous scientific inquiry. With a multidisciplinary approach, Federico II University collaborates with healthcare professionals, researchers, and industry partners to conduct high-quality clinical trials that adhere to ethical standards and regulatory requirements. Its dedication to improving health outcomes is reflected in its robust research programs and commitment to translating scientific findings into clinical practice.

Locations

Naples, , Italy

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0